慢性乙型肝炎的新生物标志物

StephenW

Gut Liver. 2019 Mar 5. doi: 10.5009/gnl18425. [Epub ahead of print]
New Biomarkers of Chronic Hepatitis B.
Mak LY1, Seto WK1,2,3, Fung J1,2, Yuen MF1,2.
Author information
Abstract

Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis B core-related antigen(HBcrAg) is a novel serum composite viral protein whose performance has been proven to be superior to that of existing viral markers. It showed good correlation with intrahepatic covalently closed-circular DNA. Its profile differs drastically inpatients in different disease phases, and the level declines with antiviral therapies. HBcrAg may be helpful for predicting hepatocellular carcinoma development and hepatitis B virus(HBV) reactivation in immunosuppressed patients. Another emerging measurable serum marker, HBV RNA, exists in the form of pregenomic RNA-containing virions. Its profile differs between patients in different disease phases in a similar manner to that of HBcrAg. HBV RNA is present in serum at lower levels than HBV DNA in treatment-naïve patients by 1-2logs. In contrast, its level is higher than HBV DNA in patients receiving nucleos(t)ide analogues (NAs). A significant decline in serum RNA was observed in patients receiving novel antiviral therapies, including core protein allosteric modulators and RIG-1/NOD2 agonists. Both HBcrAg and HBV RNA maybe helpful for predicting off-therapy sustained virological control in patients who stop long-term NA treatment.
KEYWORDS:

Biomarkers; Hepatitis B core-related antigen; Hepatitis B virus RNA

PMID:
    30919601
DOI:
    10.5009/gnl18425

StephenW

肠肝。 2019年3月5日doi：10.5009 / gnl18425。 [印刷前的电子版]
慢性乙型肝炎的新生物标志物
Mak LY1，Seto WK1,2,3，Fung J1,2，Yuen MF1,2。
作者信息
抽象

慢性乙型肝炎（CHB）感染导致临床异质性疾病结果。利用不同的病毒标志物监测治疗效果并预测CHB患者并发症的风险。乙型肝炎核心相关抗原（HBcrAg）是一种新型血清复合病毒蛋白，其性能已被证明优于现有的病毒标记物。它与肝内共价闭环DNA显示出良好的相关性。它的概况在不同疾病阶段的患者中差别很大，并且随着抗病毒治疗的水平下降。 HBcrAg可能有助于预测免疫抑制患者的肝细胞癌发展和乙型肝炎病毒（HBV）再激活。另一种新出现的可测量血清标记物HBV RNA以含有前基因组RNA的病毒粒子的形式存在。其特征在不同疾病阶段的患者中以与HBcrAg相似的方式不同。在治疗初治患者中，HBV RNA以低于HBV DNA的水平存在于1-2logs。相反，其接受核苷（酸）类似物（NAs）的患者的水平高于HBV DNA。在接受新型抗病毒治疗的患者中观察到血清RNA的显着下降，包括核心蛋白质变构调节剂和RIG-1 / NOD2激动剂。 HBcrAg和HBV RNA均可用于预测停止长期NA治疗的患者的治疗后持续病毒学控制。
关键词：

生物标志物;乙型肝炎核心相关抗原;乙型肝炎病毒RNA

结论：
    30919601
DOI：
    10.5009 / gnl18425

StephenW

www.gutnliver.org/journal/download_pdf.php?doi=10.5009/gnl18425